ZA953439B - Method of administering azithromycin - Google Patents

Method of administering azithromycin

Info

Publication number
ZA953439B
ZA953439B ZA953439A ZA953439A ZA953439B ZA 953439 B ZA953439 B ZA 953439B ZA 953439 A ZA953439 A ZA 953439A ZA 953439 A ZA953439 A ZA 953439A ZA 953439 B ZA953439 B ZA 953439B
Authority
ZA
South Africa
Prior art keywords
administering azithromycin
azithromycin
administering
Prior art date
Application number
ZA953439A
Other languages
English (en)
Inventor
William J Curatolo
George H Foulds
Hylar L Friedman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA953439(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ZA953439B publication Critical patent/ZA953439B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ZA953439A 1994-04-29 1995-04-28 Method of administering azithromycin ZA953439B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (1)

Publication Number Publication Date
ZA953439B true ZA953439B (en) 1996-10-28

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA953439A ZA953439B (en) 1994-04-29 1995-04-28 Method of administering azithromycin

Country Status (31)

Country Link
US (2) US5605889A (ru)
EP (1) EP0679400B1 (ru)
JP (3) JPH07300420A (ru)
KR (1) KR100354310B1 (ru)
CN (1) CN1088362C (ru)
AP (1) AP566A (ru)
AT (1) ATE183395T1 (ru)
AU (1) AU709328B2 (ru)
CA (1) CA2148071C (ru)
CO (1) CO4560547A1 (ru)
DE (1) DE69511451T2 (ru)
DK (1) DK0679400T3 (ru)
DZ (1) DZ1877A1 (ru)
ES (1) ES2136247T3 (ru)
FI (1) FI952060A (ru)
GR (1) GR3031290T3 (ru)
HU (1) HUT75244A (ru)
IL (1) IL113437A (ru)
LV (1) LV10918B (ru)
MA (1) MA23533A1 (ru)
NO (1) NO314386B1 (ru)
NZ (1) NZ548384A (ru)
OA (1) OA10151A (ru)
RU (1) RU2128998C1 (ru)
SI (1) SI0679400T1 (ru)
TN (1) TNSN95046A1 (ru)
TW (1) TW499311B (ru)
UA (1) UA34464C2 (ru)
UY (1) UY23935A1 (ru)
YU (1) YU49483B (ru)
ZA (1) ZA953439B (ru)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2163504T5 (es) † 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
CZ293718B6 (cs) * 1995-02-08 2004-07-14 Yamanouchi Europe B. V. Způsob přípravy granulátu obsahujícího orálně účinné beta-laktamové antibiotikum a orální dávkovací forma obsahující orálně účinné beta-laktamové antibiotikum
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) * 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
CA2323849C (en) * 1997-12-22 2002-06-11 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
WO2000059477A1 (en) * 1999-03-31 2000-10-12 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US20030219405A1 (en) * 2002-01-16 2003-11-27 Yoshihiro Sokawa Oral administration of interferon-tau
ES2260047T3 (es) * 2000-07-25 2006-11-01 Laboratorio Silanes, S.A. De C.V. Proceso de etapa unica para la preparacion de 7,16-deoxi-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihidroxi-6-etil-3,5,9,11,13,15-hexametilbiciclo(11.2.1)hexadeca-1(2)-en-ona y obtencion de una forma nueva de 9-deoxo-9a-metil-9a-homoeritromicina a.
WO2002015842A2 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
EP1339829B1 (en) * 2000-11-06 2018-10-24 Life Technologies Corporation Dry powder cell culture media and methods of production thereof
DE60139892D1 (de) * 2000-11-15 2009-10-22 Masao Sugamata Makrolidantibiotika für endometriose oder uterusmyome
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
DE60209704T2 (de) * 2001-05-22 2006-11-16 Pfizer Products Inc., Groton Neue kristallforme von azithromycin
EP1671978A1 (en) 2001-05-22 2006-06-21 Pfizer Products Inc. New Cristal Form of Azithromycin
GEP20063812B (en) * 2001-08-21 2006-05-10 Pfizer Prod Inc Single dose azithromycin for treating respirator infections
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
US6764997B2 (en) * 2001-10-18 2004-07-20 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
CN1606433A (zh) * 2001-12-21 2005-04-13 辉瑞产品公司 阿齐霉素湿法制粒法
RU2277914C2 (ru) * 2001-12-21 2006-06-20 Пфайзер Продактс Инк. Составы, содержащие азитромицин, поддающиеся прямому прессованию
KR100676025B1 (ko) * 2002-02-01 2007-01-29 화이자 프로덕츠 인코포레이티드 아지쓰로마이신의 건조 과립화 제제
JP2005527508A (ja) * 2002-03-07 2005-09-15 ヴェクトゥラ　リミテッド 経口デリバリー用急速溶融多粒子製剤
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
EP1594762A1 (en) * 2003-02-19 2005-11-16 Teva Pharmaceutical Industries Limited Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
WO2004100880A2 (en) * 2003-05-06 2004-11-25 Nirmal Mulye Controlled release formulation of erythromycin derivatives
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DE602004019288D1 (de) * 2003-07-24 2009-03-19 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform
AR045142A1 (es) 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
CA2547239A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
UA78793C2 (en) * 2003-12-04 2007-04-25 Pfizer Prod Inc Oral dosage form of azitromycin with decreased side effects
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
DE602004014805D1 (de) * 2003-12-04 2008-08-14 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
KR20070095456A (ko) * 2005-01-27 2007-09-28 알렘빅 리미티드 레베티라세탐의 서방형 제제
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
JP2008528583A (ja) * 2005-03-07 2008-07-31 テバ ファーマシューティカル インダストリーズ リミティド 経口懸濁用のアジスロマイシン粉末組成物
MX2007014872A (es) 2005-05-26 2008-02-15 Dainippon Sumitomo Pharma Co Composicion farmaceutica.
CA2618977C (en) * 2005-08-10 2014-10-21 Shionogi & Co., Ltd. Orally disintegratable tablet
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
PL230178B1 (pl) 2012-02-06 2018-09-28 Merial Ltd Weterynaryjne miękkie, nadające się do żucia kompozycje przeciwpasożytnicze obejmujące działające systemowo substancje czynne oraz zastosowania je obejmujące
CN104168895B (zh) 2012-02-28 2020-02-21 首尔制药株式会社 包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
US20150132382A1 (en) * 2013-11-11 2015-05-14 Forest Laboratories Holdings Ltd. Compositions and methods of treatment comprising fosfomycin disodium
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RU2066324C1 (ru) 1987-07-09 1996-09-10 Пфайзер Инк. Кристаллический дигидрат азитромицина и способ его получения
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
KR930702369A (ko) * 1990-10-15 1993-09-08 우에노 아키라 에리쓰로마이신 또는 그의 유도체의 2'위치 수식 화합물
TW271400B (ru) 1992-07-30 1996-03-01 Pfizer
WO1995009601A1 (en) 1993-10-01 1995-04-13 The Procter & Gamble Company Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
ES2163504T5 (es) 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.

Also Published As

Publication number Publication date
TW499311B (en) 2002-08-21
JP2005015466A (ja) 2005-01-20
CN1114879A (zh) 1996-01-17
DE69511451D1 (de) 1999-09-23
JPH07300420A (ja) 1995-11-14
LV10918A (lv) 1995-12-20
CA2148071A1 (en) 1995-10-30
UY23935A1 (es) 1995-09-12
AP566A (en) 1996-11-22
YU27195A (sh) 1999-03-04
EP0679400B1 (en) 1999-08-18
UA34464C2 (ru) 2001-03-15
JP2008231120A (ja) 2008-10-02
HU9501206D0 (en) 1995-06-28
RU95106639A (ru) 1997-01-20
NO314386B1 (no) 2003-03-17
SI0679400T1 (en) 1999-10-31
AU1771195A (en) 1995-11-09
DZ1877A1 (fr) 2002-02-17
FI952060A0 (fi) 1995-04-28
EP0679400A1 (en) 1995-11-02
GR3031290T3 (en) 1999-12-31
KR100354310B1 (ko) 2002-12-26
AU709328B2 (en) 1999-08-26
AP9500728A0 (en) 1995-04-30
CO4560547A1 (es) 1998-02-10
DE69511451T2 (de) 1999-12-09
DK0679400T3 (da) 1999-12-06
HUT75244A (en) 1997-05-28
ATE183395T1 (de) 1999-09-15
YU49483B (sh) 2006-08-17
US5605889A (en) 1997-02-25
NO951630D0 (no) 1995-04-28
MA23533A1 (fr) 1995-12-31
IL113437A0 (en) 1995-07-31
ES2136247T3 (es) 1999-11-16
CA2148071C (en) 2000-10-17
CN1088362C (zh) 2002-07-31
KR950028764A (ko) 1995-11-22
NO951630L (no) 1995-10-30
USRE39149E1 (en) 2006-06-27
NZ548384A (en) 2008-04-30
TNSN95046A1 (fr) 1996-02-06
IL113437A (en) 2001-04-30
FI952060A (fi) 1995-10-30
LV10918B (en) 1996-06-20
RU2128998C1 (ru) 1999-04-20
OA10151A (en) 1996-12-18

Similar Documents

Publication Publication Date Title
ZA953439B (en) Method of administering azithromycin
GB9410320D0 (en) Novel therapeutic method
PL320699A1 (en) Method of obtaining cephotaxime
GB9515868D0 (en) Therapeutic method
GB9523303D0 (en) Asychronous control of insertion apparatus
PL306900A1 (en) Method of obtaining 1-amino-1-methylo-3(4)-cyano-cyclohexane
GB9415902D0 (en) Method of treatment
GB2270752B (en) Diagnostic method
ZA952405B (en) Solutions of dirithromycin
GB9407335D0 (en) Method of treatment
PL301929A1 (en) Method of obtaining epichlorohydine
GB9414652D0 (en) Method of treatment
GB9414242D0 (en) Therapeutic method
GB9420524D0 (en) Method of treatment
GB9417061D0 (en) Novel method of therapy
PL306637A1 (en) Method of obtaining (e)-3-methyl-6-trimethylsilisium 4-hexen-1-ol
GB9410693D0 (en) Novel therapeutic method
GB9410326D0 (en) Novel therapeutic method
GB9411549D0 (en) Novel therapeutic method
GB9410319D0 (en) Novel therapeutic method
PL304404A1 (en) Method of obtaining allylocellulose
PL303371A1 (en) Method of obtaining perhalomethanes
PL303326A1 (en) Method of obtaining 1-phenylocyclopropanocarboxylonitrile
PL304106A1 (en) Method of obtaining saccharose-modified cofffee
PL305076A1 (en) Method of obtaining hyaluronidaze